Topic: drug reimbursement
Which biotech company does Vertex admire? Hint: It’s one some analysts think the CF drugmaker should bought a long time ago.
Takeda has scored a victory in its quest to secure reimbursement in England for lymphoma med Adcetris. But it’s only a partial victory.
Novartis’ Kisqali is playing from behind. But it just may have a shot at being No. 1 when it comes to snagging reimbursement in England.
It’s been just over six months since Biogen’s pricey Spinraza won FDA approval, and insurance coverage is looking better than some had expected.
Pfizer can fully explain its slowdown in Xtandi sales, executives told investors Tuesday. It just didn’t anticipate the hurdles when it shelled out $14 billion to gain access to the cancer fighter.
Vertex started tying compensation more closely to company performance last year, and it showed in CEO Jeff Leiden's 2016 pay.
In another sign of pharma's dwindling pricing power, Germany is on the verge of stiffening up its already strict drug pricing rules, a move that could prompt more Big Pharma companies to pull products off that market.
Just over a year ago, Sanofi and Novo Nordisk were touting their new basal insulins as fuel for their diabetes growth engines. But several payers have clamped down on those new meds--Toujeo and Tresiba, respectively--and now, Medicare Part D plans are adding to the pressure.
Celgene’s psoriasis pill Otezla won over England’s cost-effectiveness watchdogs--thanks to a discount.
The pace of hospital reforms in China needs to go faster as patient access to services continues to lag and costs are not under control.